TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24396131

Group type: EXPERIMENTAL
Intervention: Dystonia group (7 participants)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (9 healthy volunteers)
Number of subjects: 16
Study: 24396625

Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir-based regimen
Number of subjects: 32
Study: 24397612

Group type: EXPERIMENTAL
Intervention: 3CL configuration (3rd nail from lateral)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3CM configuration (3rd nail from medial)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2C configuration (2C-shaped nails, 2 × 3.5 mm)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Modified ESIN (3CL or 3CM)
Number of subjects: 17
Study: 24398064

Group type: EXPERIMENTAL
Intervention: CC2 (PillCam Colon2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CTC (Computed Tomographic Colonography)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preference for CC2 over CTC
Number of subjects: 50
Study: 24398331

Group type: EXPERIMENTAL
Intervention: Corticosteroid-sparing treatments
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: FAS mutations
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Elevated serum vitamin B12
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lymphoma risk
Number of subjects: 150

Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 150
Study: 24399330

Group type: EXPERIMENTAL
Intervention: Active hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo hormone therapy
Number of subjects: 0
Study: 24400847

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (mean daily doses: bisoprolol 5.5 mg, metoprolol 73.7 mg)
Number of subjects: 399
Study: 24400912

Group type: EXPERIMENTAL
Intervention: Set-valued dynamic treatment regimes (DTRs) that accommodate competing outcomes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exact enumeration algorithm for constructing DTRs.
Number of subjects: 0
Study: 24401226

Group type: EXPERIMENTAL
Intervention: Fructose in isocaloric exchange for other carbohydrate (n=290)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fructose providing excess energy (hypercaloric trials, n=33)
Number of subjects: 323
Study: 24401718

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2005 (HEI-2005)
Number of subjects: 494967

Group type: EXPERIMENTAL
Intervention: alternate Mediterranean Diet Score (aMED)
Number of subjects: 494967
Study: 24401885

Group type: EXPERIMENTAL
Intervention: Mucosal advancement flap combined with platelet-rich plasma
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 24402314

Group type: COMPARATOR
Intervention: Emergency endoscopic sclerotherapy (EEST)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Transjugular intrahepatic portal-systemic shunt (TIPS)
Number of subjects: 365
Study: 24402746

Group type: EXPERIMENTAL
Intervention: Brief Smell Identification Test (B-SIT)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Computed tomography and nasal endoscopy
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Nasal polyposis
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Recalcitrant disease and aspirin intolerance
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Disease-specific QOL measures (Rhinosinusitis Disability Index and Sinonasal Outcome Test)
Number of subjects: 445
Study: 24402982

Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART) - 2 sessions
Number of subjects: 1
Study: 24405647

Group type: EXPERIMENTAL
Intervention: Minor parotid anterior approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Retromandibular approach
Number of subjects: 60
Study: 24406779

Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of the superotemporal retinal artery
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of arteriovenous nicking (AVN)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging of focal arteriolar narrowing (FAN)
Number of subjects: 49
Study: 24407191

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.d. and irinotecan 180 mg m(-2) every 2 weeks (Phase II)
Number of subjects: 64
Study: 24408338

Group type: EXPERIMENTAL
Intervention: Interaction with the Speech-language pathologist (SLP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Interaction with the mother
Number of subjects: 21
Study: 24408395

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg BID
Number of subjects: 4
Study: 24408516

Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine)
Number of subjects: 247
Study: 24408973

Group type: EXPERIMENTAL
Intervention: Minimum intensity (MI) of optical coherence tomography (OCT) A-scans
Number of subjects: 24
Study: 24410126

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (1 mM) and IL13-PE (0.125 μg/ml)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (5 mM) and IL13-PE (0.25 μg/ml)
Number of subjects: 4
Study: 24410943

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily for 4 weeks
Number of subjects: 17
Study: 24411228

Group type: EXPERIMENTAL
Intervention: Two-week schedule of radiotherapy with oral capecitabine (1650 mg/m²/day)
Number of subjects: 80
Study: 24412048

Group type: EXPERIMENTAL
Intervention: ProSavin (1·9×10(7) TU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ProSavin (4·0×10(7) TU)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ProSavin (1×10(8) TU)
Number of subjects: 15
Study: 24412141

Group type: EXPERIMENTAL
Intervention: Cushing disease (CD)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone-independent CS (AICS)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cushing syndrome (CS)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Children with advanced BA
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Children with Cushing disease (CD) post-surgery
Number of subjects: 124
Study: 24412228

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily until disease progression
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44
Study: 24412444

Group type: EXPERIMENTAL
Intervention: Resting heart rate
Number of subjects: 5000
Study: 24412823

Group type: EXPERIMENTAL
Intervention: Post-induction PET (PI-PET) scan
Number of subjects: 202
Study: 24413185

Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based intervention for physical activity in cardiac rehabilitation
Number of subjects: 11
Study: 24413351

Group type: EXPERIMENTAL
Intervention: Unrecognised Obstructive Sleep Apnoea (OSA)
Number of subjects: 1200
Study: 24414130

Group type: EXPERIMENTAL
Intervention: Local determination of HER2 receptor status
Number of subjects: 196

Group type: COMPARATOR
Intervention: Central determination of HER2 receptor status
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Local determination of ER receptor status
Number of subjects: 196

Group type: COMPARATOR
Intervention: Central determination of ER receptor status
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Local determination of PR receptor status
Number of subjects: 196

Group type: COMPARATOR
Intervention: Central determination of PR receptor status
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Treatment plan alteration based on receptor status change
Number of subjects: 196
Study: 24415536

Group type: EXPERIMENTAL
Intervention: Chemotherapy (protocol I, 3 polychemotherapy blocks, delayed intensification, cranial radiotherapy, and maintenance for 2 years)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 312

Group type: COMPARATOR
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with only prednisone poor response (PPR)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Chemotherapy for MRD-HR patients
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with no CR at day 33
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Chemotherapy for patients with t(4;11) translocation
Number of subjects: 312
Study: 24415560

Group type: EXPERIMENTAL
Intervention: Oral clofarabine (1 mg to 6 mg daily for 14 or 21 days of a 28-day cycle, for up to five cycles)
Number of subjects: 22
Study: 24416138

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gemcitabine (300 mg/m2 i.v. weekly ×5 weeks) with radiation therapy (45 Gy in 25 fractions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 24416945

Group type: EXPERIMENTAL
Intervention: Electronic prescribing (e-prescribing) using a commercial EHR with clinical decision support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as traditional prescribing methods prior to e-prescribing)
Number of subjects: 20
Study: 24417450

Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant (RIF-R) mutations in Mycobacterium tuberculosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compensatory mutations in the β' subunit of RNA polymerase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient poor growth conditions
Number of subjects: 0
Study: 24417980

Group type: COMPARATOR
Intervention: CTRP-3 concentrations in patients with ACS or SAP
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Correlation of CTRP-3 levels
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Odds ratio for CAD risk in relation to CTRP-3 levels
Number of subjects: 362

Group type: COMPARATOR
Intervention: Progranulin levels
Number of subjects: 362
Study: 24418731

Group type: EXPERIMENTAL
Intervention: Medical management of pump thrombus
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Pump exchange
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Urgent transplantation
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Medical therapy for pump thrombus
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Survival at 1 year
Number of subjects: 382
Study: 24419411

Group type: EXPERIMENTAL
Intervention: EGFR mutation positive
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: EGFR mutation negative
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Demographic and clinical subgroup analysis
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Statistical significance of factors
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1482
Study: 24420643

Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1-34) 20 mcg sc daily for 24 months
Number of subjects: 23
Study: 24420806

Group type: EXPERIMENTAL
Intervention: CSH intervention schools
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Comparison schools
Number of subjects: 1157
Study: 24422672

Group type: EXPERIMENTAL
Intervention: Combination targeted therapy consisting of sorafenib, temsirolimus, and bevacizumab
Number of subjects: 1
Study: 24422782

Group type: EXPERIMENTAL
Intervention: IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate bed (68.0 Gy) in 34 fractions
Number of subjects: 40
Study: 24423017

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 1752
Study: 24423045

Group type: EXPERIMENTAL
Intervention: 2:1 formulation of follitropin alfa and lutropin alfa
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: ICSI/IVF + ICSI
Number of subjects: 2220
Study: 24423152

Group type: EXPERIMENTAL
Intervention: Rapidly reversible, sedation-related delirium
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No delirium
Number of subjects: 102

Group type: COMPARATOR
Intervention: Persistent delirium
Number of subjects: 102
Study: 24423285

Group type: EXPERIMENTAL
Intervention: LCI699 (4 mg/d, escalated to 10, 20, 40, and 100 mg/d as needed)
Number of subjects: 12
Study: 24423301

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg administered sc every 28 days
Number of subjects: 90
Study: 24423462

Group type: EXPERIMENTAL
Intervention: High-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel-based chemotherapy and long-term androgen deprivation therapy
Number of subjects: 35
Study: 24423476

Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion (4 mg/mL) via adventitial microinfusion catheter
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamethasone infusion
Number of subjects: 20
Study: 24423745

Group type: EXPERIMENTAL
Intervention: Whole body hydroxyproline production (Wb OH-PRO) assessed by stable isotope 2-D-OH-PRO for 3 hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plasma OH-PRO concentrations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation of Wb OH-PRO production with plasma OH-PRO concentrations in CF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) in hip
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) in spine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole body BMD, lung function, and body composition
Number of subjects: 15
Study: 24427455

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Neostigmine 50 µg/kg with glycopyrrolate 10 µg/kg
Number of subjects: 118
Study: 24427766

Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 474

Group type: COMPARATOR
Intervention: MMR+V
Number of subjects: 474
Study: 24428625

Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (1000 iu/m2/dose, intramuscular, 8 or 15 doses at 2-6 weeks intervals, total exposure 30 weeks)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Re-exposure to PEG-asparaginase in AAP patients
Number of subjects: 786
Study: 24428859

Group type: EXPERIMENTAL
Intervention: Single-allergen OIT (peanut)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple food OIT (up to 5 foods)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiple food OIT
Number of subjects: 40
Study: 24428877

Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients (median 0.61% (upper limits of first and third quartiles -1.22;3.2))
Number of subjects: 118

Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients with silent myocardial ischemia (SMI)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Paradoxical vasoconstriction in diabetic patients with SMI
Number of subjects: 118

Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD) in diabetic patients with coronary artery disease (CAD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Paradoxical vasoconstriction in diabetic patients with CAD
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Paradoxical vasoconstriction as a predictor for SMI
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Paradoxical vasoconstriction as a predictor for CAD
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Negative predictive value of paradoxical vasoconstriction to detect CAD
Number of subjects: 118
Study: 24428927

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 18%
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 16.4%
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) at cut-off of 21%
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Combination of hemoglobin ≤ 10 g/dL and RDW >15%
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Area under the curve for RDW
Number of subjects: 2091
Study: 24429069

Group type: EXPERIMENTAL
Intervention: Live oral Salmonella enterica serovar Typhi vaccine Ty21a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live oral S. Typhi vaccine CVD 909
Number of subjects: 0
Study: 24429093

Group type: EXPERIMENTAL
Intervention: CT lung density measurement
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 1928

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers (SP-D and sRAGE)
Number of subjects: 1928
Study: 24429274

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Lung volume measurement
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Airway resistance test
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Diffusing capacity measurement
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: All tests combined
Number of subjects: 979
Study: 24429311

Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Day 7 total RMP level (cut-off 12.50 mg/l)
Number of subjects: 110
Study: 24429336

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/day (days 1-14), bortezomib 1.0 mg/m² (days 1, 4, 8, and 11), dexamethasone 40/20 mg/day (cycles 1-4) and 20/10 mg/day (cycles 5-8)
Number of subjects: 64
Study: 24429337

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD34(+) hematopoietic progenitor cells (HPCs) mobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Globin lentiviral vector (TNS9.3.55)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vector-encoded β-chain expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable vector copy number
Number of subjects: 0
Study: 24429497

Group type: EXPERIMENTAL
Intervention: Carfilzomib (escalated from 20 to 45 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Carfilzomib (45 mg/m²), ascorbic acid (1000 mg), and cyclophosphamide (2.2 mg/kg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 37
Study: 24430093

Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: GDF-9
Number of subjects: 85

Group type: COMPARATOR
Intervention: PCOS, IH, and healthy controls
Number of subjects: 85
Study: 24431228

Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) therapy
Number of subjects: 25
Study: 24431279

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients with comorbid migraine (n = 46)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) for patients without comorbid migraine (n = 183)
Number of subjects: 229
Study: 24431907

Group type: EXPERIMENTAL
Intervention: Empirical antifungal therapy with itraconazole
Number of subjects: 391
Study: 24431909

Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA) administered intravenously once every 2 weeks (n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epoetin beta administered thrice-weekly (n=41)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CERA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 80
Study: 24432743

Group type: EXPERIMENTAL
Intervention: Blueberry juice (250 mL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anthocyanin metabolites
Number of subjects: 17
Study: 24433194

Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (three annual treatments)
Number of subjects: 3646

Group type: COMPARATOR
Intervention: Baseline-only treatment
Number of subjects: 3646

Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 3646
Study: 24433481

Group type: EXPERIMENTAL
Intervention: Basal UCP I/(I + III) ratio before MTX infusion (P1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: UCP I/(I + III) ratio at the end of MTX infusion (P2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: UCP I/(I + III) ratio on the day of hospital discharge (P3)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Change in UCP I/(I + III) ratio between P1 and P3
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Basal UCP I/(I + III) ratio
Number of subjects: 81
Study: 24433710

Group type: EXPERIMENTAL
Intervention: Negative remodeling lesions (RI <0.88)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Positive remodeling lesions (RI >1.00)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Intermediate remodeling lesions (RI 0.88 to 1.00)
Number of subjects: 697
Study: 24434094

Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement plus long-acting injectable antipsychotic (haloperidol decanoate) for 6 months
Number of subjects: 30
Study: 24434370

Group type: EXPERIMENTAL
Intervention: mtDRV/rtv (800/100 mg every 24 h)
Number of subjects: 150
Study: 24435003

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 313
Study: 24435018

Group type: EXPERIMENTAL
Intervention: Infratentorial stroke patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supratentorial stroke patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 24435467

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 4-6 g daily for 12 weeks
Number of subjects: 21
Study: 24436111

Group type: EXPERIMENTAL
Intervention: Cognitive battery including memory and learning, psychomotor speed, attention, and executive function scores in RDP patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS) motor subscore
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cognitive battery scores controlling for psychomotor speed and severity of depressive symptoms
Number of subjects: 58
Study: 24438153

Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) - additional 1 g calcium/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ - additional 10 μg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) + Vitamin D₃
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24438203

Group type: EXPERIMENTAL
Intervention: Self-administered icatibant (30-mg subcutaneous injection)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Self-administration of icatibant
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (HCP administered icatibant prior to self-administration)
Number of subjects: 151